BNA Audioconference
Wednesday, March 19, 2008
1:00 PM - 2:30 PM ET
The program will present a comprehensive review and discussion surrounding the recent suit filed by the Federal Trade Commission against Cephalon alleging that the drug company engaged in anticompetitive conduct to block the entry of generic drugs from the marketplace until 2012 by paying off four generic manufacturers.
This program will be of interest to transactional lawyers who practice in health law and compliance; intellectual property attorneys; antitrust attorneys; and in-house counsel within the industry.
